Status:
UNKNOWN
Fibrinogen Concentrate in Isolated Traumatic Brain Injury
Lead Sponsor:
Leila Dehghani
Conditions:
Traumatic Brain Injury
Hemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Fibrinogen is a unique precursor of fibrin and cannot be compensated for by other coagulation factors. If plasma fibrinogen concentrations are insufficient, hemostatic clots cannot be formed with the ...
Eligibility Criteria
Inclusion
- Patients with severe isolated traumatic brain injury.
Exclusion
- Severe abdomen or extremities trauma.
- Severe bleeding from abdomen or extremities.
- Congenital coagulopathy (Hemophilia, protein S and C deficiency, Factor 5 Leiden deficiency and ...).
- Warfarin, Heparin, Enoxaparin, Dabigatran and other anticoagulation drugs consumption.
Key Trial Info
Start Date :
October 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 21 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03304899
Start Date
October 23 2018
End Date
January 21 2020
Last Update
February 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Isfahan university of medical science.
Isfahan, Iran